MX381271B - Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana - Google Patents
Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacterianaInfo
- Publication number
- MX381271B MX381271B MX2014000066A MX2014000066A MX381271B MX 381271 B MX381271 B MX 381271B MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 381271 B MX381271 B MX 381271B
- Authority
- MX
- Mexico
- Prior art keywords
- gel formulations
- bacterial vaginosis
- treat bacterial
- metronidazole
- mucoadhesive gel
- Prior art date
Links
- 208000004926 Bacterial Vaginosis Diseases 0.000 title abstract 2
- 208000037009 Vaginitis bacterial Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000282 metronidazole Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502285P | 2011-06-28 | 2011-06-28 | |
| US201161508058P | 2011-07-14 | 2011-07-14 | |
| PCT/US2012/044738 WO2013003646A1 (en) | 2011-06-28 | 2012-06-28 | High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000066A MX2014000066A (es) | 2014-05-01 |
| MX381271B true MX381271B (es) | 2025-03-11 |
Family
ID=47391265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000066A MX381271B (es) | 2011-06-28 | 2012-06-28 | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8946276B2 (enExample) |
| EP (1) | EP2725904B1 (enExample) |
| JP (2) | JP5986632B2 (enExample) |
| CN (2) | CN103763925A (enExample) |
| AU (2) | AU2012275292B2 (enExample) |
| BR (1) | BR112013033759B1 (enExample) |
| CA (2) | CA3054236A1 (enExample) |
| MX (1) | MX381271B (enExample) |
| WO (1) | WO2013003646A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013187984A1 (en) | 2012-06-13 | 2013-12-19 | Evofem, Inc. | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| CA2916002A1 (en) | 2013-06-25 | 2014-12-31 | Mission Pharmacal Company | Novel formulations for the treatment of vaginal disorders |
| NZ722215A (en) | 2013-12-19 | 2019-02-22 | Evofem Inc | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
| AU2015311674B2 (en) | 2014-09-05 | 2018-03-08 | Evofem Biosciences, Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| CA2988082C (en) | 2015-06-01 | 2020-09-29 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| WO2017165836A1 (en) * | 2016-03-24 | 2017-09-28 | Rutgers, The State University Of New Jersey | Antibacterial agents |
| AU2017338748A1 (en) * | 2016-10-04 | 2019-05-02 | Evofem Inc. | Method of treatment and prevention of bacterial vaginosis |
| SE1750680A1 (en) * | 2017-05-30 | 2018-12-01 | Peptonic Medical Ab | Composition for treating or preventing climacteric disorders |
| US20200126094A1 (en) * | 2018-10-19 | 2020-04-23 | BioIDC, Inc. | Medical research fraud detection system and software |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
| ATE67667T1 (de) | 1987-03-20 | 1991-10-15 | Curatek Pharmaceuticals | Neue topische metronidazol-formulierungen. |
| US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| CA1337279C (en) | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| EP0537784B1 (en) | 1991-10-18 | 1995-03-01 | Dow Corning Corporation | Silicone pressure sensitive adhesives having enhanced adhesion to low energy substrates |
| IT1284874B1 (it) * | 1996-08-02 | 1998-05-22 | Farmigea Spa | Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici |
| GB9626513D0 (en) | 1996-12-20 | 1997-02-05 | Bioglan Ireland R & D Ltd | A pharmaceutical composition |
| DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
| WO1998014768A2 (en) | 1997-10-06 | 1998-04-09 | Schwartz Sorell L | Transdermal chemical monitoring device |
| US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6881726B2 (en) | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
| US7368122B1 (en) | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US7456207B2 (en) * | 2003-09-25 | 2008-11-25 | Teva Pharmaceuticals Usa, Inc. | Vaginal pharmaceutical compositions and methods for preparing them |
| FR2887149B1 (fr) | 2005-06-17 | 2007-08-03 | Galderma Sa | Procede de solubilisation du metronidazole |
| US20060093675A1 (en) | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| FR2882552B1 (fr) | 2005-02-25 | 2008-12-26 | Galderma Sa | Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation |
| CA2609953A1 (en) | 2005-05-09 | 2007-04-12 | Foamix Ltd. | Saccharide foamable compositions |
| AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
| FR2890560B1 (fr) | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation |
| FR2890559B1 (fr) | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour la preparation |
| US20070105788A1 (en) | 2005-11-09 | 2007-05-10 | Serena Mraz-Gernhard | Azithromycin for treatment of granulomatous rosacea |
| BRPI0620908A2 (pt) | 2006-01-05 | 2011-11-29 | Drugtech Corp | composição farmacêutica, sistema de distribuição antibacteriana e antifúngica vaginal e uso da composição farmacêutica |
| FR2899475A1 (fr) | 2006-04-10 | 2007-10-12 | Galderma Res & Dev | Composition pharmaceutique pour le traitement de la rosacee |
| WO2008038140A2 (en) | 2006-06-07 | 2008-04-03 | Foamix Ltd. | Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof |
| US20080287513A1 (en) | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080287515A1 (en) * | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080287514A1 (en) | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080312304A1 (en) | 2007-06-13 | 2008-12-18 | Jerry Zhang | Topical compositions containing metronidazole |
| US7893097B2 (en) | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
| WO2010047831A1 (en) | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
| KR20130018739A (ko) | 2010-03-03 | 2013-02-25 | 네오큐티스 에스아 | 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법 |
-
2012
- 2012-06-28 BR BR112013033759-1A patent/BR112013033759B1/pt active IP Right Grant
- 2012-06-28 CN CN201280040540.1A patent/CN103763925A/zh active Pending
- 2012-06-28 EP EP12804805.5A patent/EP2725904B1/en active Active
- 2012-06-28 CA CA3054236A patent/CA3054236A1/en not_active Abandoned
- 2012-06-28 CN CN201710998632.5A patent/CN107823123A/zh active Pending
- 2012-06-28 MX MX2014000066A patent/MX381271B/es unknown
- 2012-06-28 AU AU2012275292A patent/AU2012275292B2/en active Active
- 2012-06-28 CA CA2840571A patent/CA2840571C/en active Active
- 2012-06-28 US US13/536,960 patent/US8946276B2/en active Active
- 2012-06-28 WO PCT/US2012/044738 patent/WO2013003646A1/en not_active Ceased
- 2012-06-28 JP JP2014519052A patent/JP5986632B2/ja active Active
- 2012-08-23 US US13/593,386 patent/US9198858B2/en active Active
-
2015
- 2015-10-23 US US14/921,737 patent/US10238634B2/en active Active
-
2016
- 2016-02-09 AU AU2016200825A patent/AU2016200825B2/en active Active
- 2016-08-05 JP JP2016154447A patent/JP6235087B2/ja active Active
-
2019
- 2019-01-14 US US16/247,497 patent/US10596155B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9198858B2 (en) | 2015-12-01 |
| BR112013033759A8 (pt) | 2018-07-31 |
| BR112013033759B1 (pt) | 2021-05-25 |
| US20160106714A1 (en) | 2016-04-21 |
| AU2012275292B2 (en) | 2015-11-12 |
| AU2012275292A1 (en) | 2014-01-23 |
| CA2840571A1 (en) | 2013-01-03 |
| BR112013033759A2 (pt) | 2016-08-16 |
| JP6235087B2 (ja) | 2017-11-22 |
| AU2016200825A1 (en) | 2016-03-03 |
| WO2013003646A1 (en) | 2013-01-03 |
| US20130005785A1 (en) | 2013-01-03 |
| US8946276B2 (en) | 2015-02-03 |
| JP5986632B2 (ja) | 2016-09-06 |
| CN107823123A (zh) | 2018-03-23 |
| CA3054236A1 (en) | 2013-01-03 |
| US20190183859A1 (en) | 2019-06-20 |
| JP2014518272A (ja) | 2014-07-28 |
| CN103763925A (zh) | 2014-04-30 |
| EP2725904A1 (en) | 2014-05-07 |
| EP2725904A4 (en) | 2014-12-10 |
| EP2725904B1 (en) | 2024-12-11 |
| JP2017014248A (ja) | 2017-01-19 |
| US10238634B2 (en) | 2019-03-26 |
| MX2014000066A (es) | 2014-05-01 |
| US10596155B2 (en) | 2020-03-24 |
| CA2840571C (en) | 2020-03-24 |
| AU2016200825B2 (en) | 2017-10-26 |
| US20130005787A1 (en) | 2013-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381271B (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| CO6351786A2 (es) | Inkibidores de la cinasa map p38 | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| MX2008016453A (es) | Composiciones y metodos para tratar infecciones parasitas. | |
| UA110103C2 (uk) | Модифікований туберкульозний антиген | |
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| MX349796B (es) | Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10. | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| EA201370018A1 (ru) | Составы рифаксимина и их применение | |
| UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
| UY33276A (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso | |
| MX377170B (es) | Composiciones de gel de brimonidina y metodos de uso. | |
| CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| UA109557C2 (uk) | Похідні 2-піперазин-1-іл-4h-1,3-бензотіазин-4-ону та їх застосування для лікування інфекцій у ссавців | |
| MX2014006686A (es) | Derivaods novedosos de pirrol. | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual |